Choose plant-derived
ESTRACE® CREAM

The #1-prescribed FDA-approved treatment for VVA among OB/GYNs1

Why choose ESTRACE®?

ESTRACE® helps maintain vulvar and vaginal health.

ESTRACE® CREAM is a local estrogen therapy that treats moderate to severe VVA symptoms in and around the vagina.2

  • Plant-derived, 17β-estradiol is structurally and chemically identical to endogenous estrogen2,3
    • There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen doses

The ESTRACE® CREAM Experience

  • Emollient-based
    • Formulated with stearyl alcohol, an emollient that may prevent moisture loss2,4
  • Nonliquefying
    • Formulated with a nonliquefying base that remains viscous at body temperature5
  • Flexible dosing to meet individual patient needs6

Is your postmenopausal patient using a lubricant? Ask her if it’s helping.

Some women may be reluctant to tell you that they are experiencing moderate to severe vaginal symptoms. Your patient may not know that she has VVA or that it is a chronic condition.7,8

See survey results.

When a lubricant isn't enough, and local estrogen therapy is appropriate, choose ESTRACE®.

Learn more about ESTRACE®

More

Resources for your practice.

ESTRACE® provides resources to help support your office and recommendations, including patient savings cards, samples, and patient materials.

Find helpful resources


  1. IMS Health, Inc. National Prescription AuditTM (NPA): January 2016-December 2016 (information used under license from IMS Health, Inc., which expressly reserves all rights, including rights of copying).
  2. ESTRACE® CREAM [package insert]. Rockaway, NJ: Warner Chilcott (US), LLC; December 2011.
  3. Harvard Health Publications Website. What are bioidentical hormones? www.health.harvard.edu/newsweek/What-are-bioidentical-hormones.htm. Accessed March 8, 2017.
  4. Stearyl alcohol. ChemicalLand21 Website; www.chemicalland21.com/industrialchem/solalc/STEARYL%20ALCOHOL.htm. Accessed March 8, 2017.
  5. Data on file. Clinical Study Report RR09111.0. Allergan: Parsippany, NJ.
  6. Lynch C. Vaginal estrogen therapy for the treatment of atrophic vaginitis. J Womens Health. 2009:18(10);1595-1606.
  7. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA). Results from an international survey. Climacteric. 2012;15:36-44.
  8. Wysocki S, Kingsberg S, Krychman M. Management of Vaginal Atrophy: Implications from the REVIVE Survey. Clin Med Insights Reprod Health. 2014;8:23-30. doi: 10.4137/CMRH.S14498.
Important Safety Information
Estrogens increase the risk of endometrial cancer

Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses.

Cardiovascular and other risks

Estrogens with or without progestins should not be used for the prevention of cardiovascular disease.

The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo.

The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens-plus-medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen-alone therapy.

Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

ESTRACE should not be used in women with undiagnosed abnormal genital bleeding; known, suspected or history of breast cancer; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism or a history of these conditions; active or recent arterial thromboembolic disease (for example, stroke, myocardial infarction); liver dysfunction or disease; hypersensitivity to the ingredients of ESTRACE; or known or suspected pregnancy. Other warnings include: increased risk of breast cancer, gallbladder disease, hypercalcemia and visual abnormalities.

Blood pressure should be monitored at regular intervals with estrogen use, and caution should be exercised in patients with impaired liver function and those with severe hypocalcemia. Patients dependent on thyroid hormone replacement therapy should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range. Endometriosis may be exacerbated in women treated post-hysterectomy with estrogen alone therapy. The addition of progestins should be considered in these patients.

The most common side effects include headache, breast tenderness, irregular vaginal bleeding or spotting, stomach/abdominal cramps, bloating, nausea and vomiting, hair loss, and vaginal burning, irritation, and itching.

Systemic absorption may occur with the use of ESTRACE Cream. The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account.

Indications and Usage

ESTRACE® (estradiol vaginal cream, USP, 0.01%) is indicated in the treatment of vulvar and vaginal atrophy due to menopause.

Please see full Prescribing Information.

More
Important Safety Information
Estrogens increase the risk of endometrial cancer

Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses.

Cardiovascular and other risks

Estrogens with or without progestins should not be used for the prevention of cardiovascular disease.

The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo.

The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens-plus-medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen-alone therapy.

Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

ESTRACE should not be used in women with undiagnosed abnormal genital bleeding; known, suspected or history of breast cancer; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism or a history of these conditions; active or recent arterial thromboembolic disease (for example, stroke, myocardial infarction); liver dysfunction or disease; hypersensitivity to the ingredients of ESTRACE; or known or suspected pregnancy. Other warnings include: increased risk of breast cancer, gallbladder disease, hypercalcemia and visual abnormalities.

Blood pressure should be monitored at regular intervals with estrogen use, and caution should be exercised in patients with impaired liver function and those with severe hypocalcemia. Patients dependent on thyroid hormone replacement therapy should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range. Endometriosis may be exacerbated in women treated post-hysterectomy with estrogen alone therapy. The addition of progestins should be considered in these patients.

The most common side effects include headache, breast tenderness, irregular vaginal bleeding or spotting, stomach/abdominal cramps, bloating, nausea and vomiting, hair loss, and vaginal burning, irritation, and itching.

Systemic absorption may occur with the use of ESTRACE Cream. The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account.

Indications and Usage

ESTRACE® (estradiol vaginal cream, USP, 0.01%) is indicated in the treatment of vulvar and vaginal atrophy due to menopause.

Please see full Prescribing Information.